ECO Animal Health - HY Results - Investor Presentation video - 2nd December 2025

David Hallas (CEO) and Chris Wilks (CFO) of ECO Animal Health conducted a live presentation covering the company's Interim Results for the period to 30th September. Highlights included a 19% increase in Group Revenue, and Gross Margins rising to 49.6% (H1 2024: 40.3%), driven by improved pricing and lower input costs.

Management highlighted the Positive Opinion received ahead of schedule from the European Medicines Agency for ECOVAXXIN® MS, the Group's poultry vaccine against Mycoplasma synoviae, establishing an anticipated EU commercial launch in H2 CY2026. The team provided a detailed financial review included an increase in adjusted EBITDA and cash balances, updated viewers on the R&D growth engine, and then answered a range of questions submitted by investors.

The full video has been divided into chapters, for ease of viewing, as below:
0:00:03 Introduction & H1 summary
0:02:41 Financial highlights
0:06:55 ECO in short
0:10:48 Financial review
0:23:48 R&D growth engine
0:27:58 Summary & Outlook
0:31:07 Questions & Answers